Oany Arafat Rahman, Mia Mamun, Pervin Tahmina, Alyami Salem Ali, Moni Mohammad Ali
Department of Biotechnology and Genetic Engineering, Faculty of Life Science, Mawlana Bhashani Science and Technology University, Tangail 1902, Bangladesh.
Aristopharma Limited, Dhaka 1000, Bangladesh.
J Pers Med. 2021 Apr 30;11(5):363. doi: 10.3390/jpm11050363.
Nowadays, cervical cancer (CC) is treated as the leading cancer among women throughout the world. Despite effective vaccination and improved surgery and treatment, CC retains its fatality rate of about half of the infected population globally. The major screening biomarkers and therapeutic target identification have now become a global concern. In the present study, we have employed systems biology approaches to retrieve the potential biomarkers and pathways from transcriptomic profiling. Initially, we have identified 76 of each up-regulated and down-regulated gene from a total of 4643 differentially expressed genes. The up-regulatory genes mainly concentrate on immune-inflammatory responses, and the down-regulatory genes are on receptor binding and gamma-glutamyltransferase. The involved pathways associated with these genes were also assessed through pathway enrichment, and we mainly focused on different cancer pathways, immunoresponse, and cell cycle pathways. After the subsequent enrichment of these genes, we have identified 12 hub genes, which play a crucial role in CC and are verified by expression profile analysis. From our study, we have found that genes LILRB2 and CYBB play crucial roles in CC, as reported here for the first time. Furthermore, the survivability of the hub genes was also assessed, and among them, finally, CXCR4 has been identified as one of the most potential differentially expressed genes that might play a vital role in the survival of CC patients. Thus, CXCR4 could be used as a prognostic and/or diagnostic biomarker and a drug target for CC.
如今，宫颈癌（CC）被视为全球女性中的主要癌症。尽管有有效的疫苗接种以及手术和治疗方法的改进，但宫颈癌在全球范围内仍保持着约一半感染人群的死亡率。主要筛查生物标志物和治疗靶点的识别现已成为全球关注的问题。在本研究中，我们采用系统生物学方法从转录组分析中检索潜在的生物标志物和信号通路。最初，我们从总共4643个差异表达基因中分别鉴定出76个上调基因和76个下调基因。上调基因主要集中在免疫炎症反应，而下调基因则集中在受体结合和γ-谷氨酰转移酶方面。还通过通路富集评估了与这些基因相关的涉及通路，我们主要关注不同的癌症通路、免疫反应和细胞周期通路。在对这些基因进行后续富集后，我们鉴定出12个核心基因，它们在宫颈癌中起关键作用，并通过表达谱分析得到验证。从我们的研究中，我们发现基因LILRB2和CYBB在宫颈癌中起关键作用，这是首次在此报道。此外，还评估了核心基因的生存能力，最终，CXCR4被确定为最具潜力的差异表达基因之一，可能在宫颈癌患者的生存中起重要作用。因此，CXCR4可作为宫颈癌的预后和/或诊断生物标志物以及药物靶点。
